^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SLAMF6 expression

    i
    Other names: SLAMF6, SLAM Family Member 6, NTB-A, KALI, SF2000, KALIb, Ly108, CD352, NTBA, Activating NK Receptor, NK-T-B-Antigen, Natural Killer-, T- And B-Cell Antigen, NTBA Receptor, CD352 Antigen
    Entrez ID:
    114836
    11ms
    Clinical and immunological relevance of SLAMF6 expression in the tumor microenvironment of breast cancer and melanoma. (PubMed, Sci Rep)
    Single-cell profiling of breast cancer tumor microenvironment reveals SLAMF6 expression overlaps CD8 T cells with a T-effector signature, which includes subsets expressing TCF7, memory and effector-related genes, analogous to progenitor-exhausted T cells. These findings illustrate the significance of SLAMF6 in the tumor as a marker for better effector responses, and provide insights into the predictive and prognostic determinants for cancer patients.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SLAMF6 (SLAM Family Member 6) • TCF7 (Transcription Factor 7)
    |
    CD8 expression • SLAMF6 expression
    1year
    The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies (ASH 2023)
    The optimal dosing schedule of bispecific antibodies has yet to be determined. Our results support a more extended dose schedule to allow T-cell-recovery between BsAb administrations. Whether such a strategy will result in higher antitumor efficacy or reduced susceptibility to infections, has to be evaluated in future studies.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD27 (CD27 Molecule) • SLAMF6 (SLAM Family Member 6) • KLRG1 (Killer Cell Lectin Like Receptor G1)
    |
    SLAMF6 expression
    over1year
    Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8 T cells to demote the antitumor immunity. (PubMed, BMC Med)
    Abnormal generation of IL-17A mainly repressed tumor infiltration of stem-like exhausted CTLs. ICB-based immunotherapeutic efficacy could be upgraded with administration of anti-IL-17A, when treatment-related IL-17A elevation occurred due to tissue damage, such as acute colitis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • ICAM1 (Intercellular adhesion molecule 1) • IL17A (Interleukin 17A) • SLAMF6 (SLAM Family Member 6)
    |
    IL1A elevation • SLAMF6 expression • IL17A elevation